<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02214134</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-1335-LCG-PBG</org_study_id>
    <nct_id>NCT02214134</nct_id>
  </id_info>
  <brief_title>SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access</brief_title>
  <acronym>SPECTAlung</acronym>
  <official_title>SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Thoracic Oncology Platform</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <authority>Slovenia: Ethics Committee</authority>
    <authority>Poland: Ethics Committee</authority>
    <authority>Spain: Ethics Committee</authority>
    <authority>Ireland: Research Ethics Committee</authority>
    <authority>Denmark: Ethics Committee</authority>
    <authority>Italy: Ethics Committee</authority>
    <authority>Switzerland: Ethikkommission</authority>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <authority>Germany: Ethics Commission</authority>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SPECTAlung is a program aiming at screening patients with thoracic tumors to identify the
      molecular characteristics of their disease. The thoracic tumors include lung cancer,
      malignant pleural mesothelioma, thymoma or thymic carcinoma at any stage. Once the molecular
      characteristics are identified, there might be the possibility to offer these patients
      access to targeted clinical trials.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Number of patients with thoracic malignancy (lung cancer, MPM and thymic malignancies) screened and efficiently allocated to biomarker-driven clinical trials.</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients for whom the description of the biomarkers and correlation to clinical/pathological characteristics can be performed.</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of exploratory/future research projects developped</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">3500</enrollment>
  <condition>Any Stage of Lung Cancer (Any Histotype)</condition>
  <condition>Any Stage of Malignant Pleural Mesothelioma</condition>
  <condition>Any Stage of Any Thymic Malignancy</condition>
  <arm_group>
    <arm_group_label>Lung cancer</arm_group_label>
    <description>Patients with diagnosis of lung cancer at any stage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Malignant pleural mesothelioma</arm_group_label>
    <description>Patients with diagnosis of malignant pleural mesothelioma at any stage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thymic malignancy</arm_group_label>
    <description>Patients with diagnosis of thymic malignancy at any stage</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Tumour markers testing</intervention_name>
    <arm_group_label>Lung cancer</arm_group_label>
    <arm_group_label>Malignant pleural mesothelioma</arm_group_label>
    <arm_group_label>Thymic malignancy</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      FFPE blocks of tumour tissue Blood samples Pleural effusion samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with pathologically confirmed lung cancer, MPM, thymoma or thymic carcinoma at
        any stage.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed lung cancer, MPM, thymoma or thymic carcinoma at any stage;

          -  Mandatory availability of adequate Human Biological Material (HBM): FFPE tissue
             sample from the primary tumor, recurrent tumor, metastasis, obtained at the time of
             primary surgery or biopsy; minimal amount requested is detailed in the HBM
             guidelines; inclusion of samples taken at any recurrence diagnosed during follow-up
             is strongly encouraged but optional;

          -  Centrally performed confirmation of tumor tissue adequacy in terms of quality/
             quantity for central screening;

          -  Age â‰¥ 18 years;

          -  At least three months life-expectancy;

          -  Written informed consent according to ICH/GCP and national/local regulations.

        Exclusion Criteria:

          -  Any active malignancy, except pT1-2 prostatic cancer Gleason score &lt; 6, non
             melanomatous skin cancer or carcinoma in situ of the cervix, in the 5 years before
             study entry;

          -  Active hepatitis B/C or HIV;

          -  Any secondary malignancy;

          -  Any severe organ dysfunction or other comorbidities that may prevent the inclusion
             into clinical trials.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Besse, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonathan Steuve, Ms</last_name>
    <phone>+32 2 774 10 39</phone>
    <email>jonathan.steuve@eortc.be</email>
  </overall_contact>
  <verification_date>August 2014</verification_date>
  <lastchanged_date>August 8, 2014</lastchanged_date>
  <firstreceived_date>August 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung cancer</keyword>
  <keyword>Malignant pleural mesothelioma</keyword>
  <keyword>Thymic malignancy</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Screening</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Thoracic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
